Table 1.
Clinicopathological Characteristics of 16 Patients.
| Characteristic | n (%) |
|---|---|
| Age at diagnosis (years) | |
| >45 | 11 (68.8) |
| ≤45 | 5 (31.2) |
| Unknown | 0 |
| Whether received adjuvant HT | |
| Yes | 11 (68.8) |
| No | 5 (31.2) |
| Unknown | 0 |
| Therapeutic status of adjuvant HT | |
| Relapse within 2 years while on adjuvant HT | 0 (0.0) |
| Relapse after 2 years while on adjuvant HT | 4 (36.4) |
| Relapse within 1 year of completing adjuvant HT | 0 (0.0) |
| Relapse after 1 year of completing adjuvant HT | 7 (63.6) |
| Not applicable | 5 |
| Regimens prior to exemestane in first line | |
| Antharcycline and/or Taxanes | 9 (56.25) |
| Trastuzumab and/or pertuzumab | 2 (12.5) |
| None | 7 (43.75) |
| Unknown | 0 |
| Histology of primary tumor | |
| Ductal | 15 (93.8) |
| Lobular | 1 (6.2) |
| Others | 0 (0.0) |
| Unknown | 0 |
| Initial HER2 status | |
| Positive | 3 (20.0) |
| Negative | 12 (80.0) |
| Unknown | 1 |
| Initial TNM stage | |
| I | 1 (6.2) |
| II | 8 (50.0) |
| III | 2 (12.5) |
| IV | 5 (31.3) |
| Unknown | 0 |
| Sites of metastases at relapse | |
| Liver | 3 (18.8) |
| Lung | 8 (50.0) |
| Brain | 1 (6.3) |
| Bone | 5 (31.3) |
| Lymph node | 7 (43.8) |
| Chest wall | 1 (6.3) |
| Unknown | 0 |
Abbreviation: HT, hormone therapy; TNM, Tumor Node Metastasis.